Durvalumab as neoadjuvant therapy for muscle-invasive bladder cancer: Preliminary results from the Bladder Cancer Signal Seeking Trial (BLASST)-2.
Xiao X. Wei(Dana-Farber Cancer Institute), Guru Sonpavde(AdventHealth Orlando), Eliezer M. Van Allen(Dana-Farber Cancer Institute), Richard J. Lee(La Roche College), Kerry L. Kilbridge(Dana-Farber Cancer Institute), Alyssa Klein(Stanford Medicine), Marios Giannakis(Broad Institute), Mariano Severgnini(Dana-Farber Cancer Institute), Bradley A. McGregor(Harvard University), Graeme S. Steele(Brigham and Women's Hospital), Xīn Gào(Qingdao University), Matthew Mossanen(Massachusetts General Hospital), Mark A. Preston(Brigham and Women's Hospital), Matthew D. Ingham(Brigham and Women's Hospital)
Cited by 20
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k